"The
Report EpiCast Report: Psoriatic Arthritis - Epidemiology Forecast to
2025 provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
Psoriatic
arthritis (PsA) is a chronic inflammatory arthropathy that may be
progressive in nature and can lead to severe joint damage and
disability. The disease is considered to be rare in the general
population, but PsA may affect up to 30% of persons with psoriasis
(Ogdie and Gelfand, 2011; NPF, 2016).
In
the 7MM, GlobalData epidemiologists forecast that the diagnosed
prevalent cases of PsA will increase from 1,044,022 cases in 2015 to
1,107,253 cases in 2025, at an Annual Growth Rate (AGR) of 0.61%. The
US will have the highest number of diagnosed prevalent cases of PsA
among the 7MM throughout the forecast period, while Japan will have
the least.
View Report @
http://www.marketresearchreports.biz/analysis/903166
GlobalData
epidemiologists provided an alternate forecast that models an
increased diagnosis rate, as indicated by primary research involving
high prescribing physician surveys. The results of the survey suggest
that the diagnosis rate of PsA is likely to improve during the
forecast period, from 2015-2025. Based on the alternative forecast of
diagnosed prevalent cases, and using diagnosis rates obtained through
primary market research, GlobalData epidemiologists forecast that in
2015 there were 1,044,022 diagnosed prevalent cases of PsA; this is
expected to grow to 1,520,469 cases by 2025, at an AGR of 4.56%.
GlobalDatas
forecast is strengthened by the use of peer-reviewed,
country-specific publications, which provided the total number of
diagnosed cases or diagnosed prevalent cases in each market. The use
of studies that supplied diagnosed prevalence based on CASPAR
criteria and medical records in countries where CASPAR is
predominantly used provides a significant measure of the underlying
burden of PsA in all of the 7MM. The use of a consistent methodology
across the 7MM to forecast the diagnosed prevalent cases of PsA
allows for a meaningful comparison of the forecast diagnosed
prevalent cases of PsA in these markets. Additionally, GlobalData
epidemiologists provided the diagnosed prevalent cases of PsA in each
of the 7MM, segmented by type (symmetric, asymmetric, distal,
spondylitis, and arthritis mutilans), which can be of importance for
forecasting the prognosis and course of treatment.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/903166
Scope
-
The Psoriatic Arthritis (PsA) EpiCast Report provides an overview of
the risk factors and global trends of NSCLC in the 7MM (US, France,
Germany, Italy, Spain, UK, and Japan). It includes a base 10-year
epidemiological forecast for the diagnosed prevalent cases. The
diagnosed prevalent cases of PsA are further segmented by sex, age,
type as defined by the Moll and Wright criteria (symmetric,
asymmetric, distal, spondylitis, and arthritis mutilans), and by
peripheral or axial joint involvement. Additionally, GlobalData
epidemiologists include an alternate 10-year epidemiological forecast
of the diagnosed incident cases of PsA based on primary market
research, which includes an adjustment for an improving diagnosis
rate over the forecast period.
-
The PsA epidemiology report is written and developed by Masters- and
PhD-level epidemiologists.
-
The EpiCast Report is in-depth, high quality, transparent and
market-driven, providing expert analysis of disease trends in the
7MM.
Reasons to buy
-
The PsA EpiCast report will allow you to -
-
Develop business strategies by understanding the trends shaping and
driving the global PsA market.
-
Quantify patient populations in the global PsA market to improve
product design, pricing, and launch plans.
-
Organize sales and marketing efforts by identifying the age groups
and sex that present the best opportunities for PsA therapeutics in
each of the markets covered.
-
Compare patient population potentials in various type and understand
how might changes in diagnosis rate impact patient size
For More latest Reports Under
Chemicals Category:
Table
of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Epidemiology 7
2.1 Disease Background 7
2.2 Risk Factors and Comorbidities
9
2.3 Global Trends 10
2.4 Forecast Methodology 11
2.4.1 Sources Used 11
2.4.2 Forecast Assumptions and
Methods 12
2.4.3 Sources Not Used 19
2.5 Epidemiological Forecast for
PsA (2015-2025) 20
2.5.1 Diagnosed Prevalent Cases of
PsA 20
2.5.2 Age-Specific Diagnosed
Prevalent Cases of PsA 22
2.5.3 Sex-Specific Diagnosed
Prevalent Cases of PsA 24
2.5.4 Age-Standardized Diagnosed
Prevalence of PsA 26
2.5.5 Diagnosed Prevalent Cases by
Type 28
2.5.6 Diagnosed Prevalent Cases by
Joint Involvement 29
2.6 Alternative Forecast of
Diagnosed Prevalent Cases of PsA 29
2.7 Discussion 31
2.7.1 Epidemiological Forecast
Insight 31
2.7.2 Limitations of the Analysis
32
2.7.3 Strengths of the Analysis 33
3 Appendix 35
3.1 Physicians and Specialists
Included in This Report 38
3.2 About the Authors 38
3.2.1 Epidemiologists 38
3.2.2 Reviewers 38
3.2.3 Global Director of Therapy
Analysis and Epidemiology 39
3.3 About GlobalData 40
3.4 About EpiCast 40
3.5 Disclaimer 41
Read our latest Press Release
at http://www.marketresearchreports.biz/pressreleases
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment